Blood test may lead to targeted therapy for prostate cancer

Conclusion Genetic testing is becoming more common in cancer treatment as a way of tailoring treatment to the individual cancer. It's already used in breast cancer, for example. This test could help identify which men that have not responded to hormone treatment are most likely to benefit from two of the newer prostate cancer drugs. It is good news, because men could then be spared treatment that is unlikely to help them, and directed towards more suitable treatment options. Also, both of these newer drugs are very expensive, so a suitable test could save the NHS a great deal of money. Meanwhile, those men who are likely to benefit will take the drug knowing it's likely to help. However, we're some way off being able to use the test in practice. This research shows that, among a group of 265 men, those with multiple copies of the androgen receptor gene did worse after treatment than those without. That doesn't prove that selecting patients for treatment based on AR gene status will improve outcomes. We need to see studies that select patients for treatment based on their test results, and follow them up to see how they do, to be sure the test is truly helpful. Links To The Headlines Prostate cancer: Blood test could help target treatment. BBC News, May 4 2017 Blood test could help prostate cancer treatment. ITV News, May 4 2017 £50 blood test boosts chances of surviving prostate cancer. The Times, May 4 2017 (subscription required) Links To Science Conteduc...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Medication Source Type: news

Related Links:

Publication date: Available online 6 November 2018Source: Journal of Bone OncologyAuthor(s): Stella D'Oronzo, Robert Coleman, Janet Brown, Francesco SilvestrisAbstractBone metastases (BM) are a common complication of cancer, whose management often requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with BM may still experience skeletal-related events and symptomatic skeletal events, with detrimental impact on quality of life and survival.A deeper knowledge of the mechanisms underlying the onset of lytic and sclerotic BM has been acquired in the last decades, leading to the development o...
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
Abstract Background: Cancer survivors suffer from many comorbid conditions even after the cure of their cancers beyond 5 years. We explored the differences in the association of comorbid conditions between the cancer survivors and patients without cancer. Methods: Electronic medical records of 280 adult cancer survivors and 280 age-matched patients without cancer in our suburban internal medicine office were reviewed. Results: Mean age of the cancer survivors was 72.5 ± 13.1 years, and the age of the patients without cancer was 72.5 ± 12.8 years. The number of male cancer survivors was sign...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Med Res Source Type: research
To the Editor: We thank Professor Spratt for his editorial, which accompanied publication of our manuscript that assessed Ki67 as a prognostic and predictive biomarker after radiation therapy in localized prostate cancer (1, 2). The editorial mentions a rather small increase in biochemical recurrence per unit increase in Ki67, which warrants clarification. We assessed Ki67 as a continuous variable using a percentage scale, as recommended in both the Transparent Reporting of a Multivariate Prediction Model for Individual Prognosis or Diagnosis statement (3) and recent literature relating to optimal use of Ki67 in breast cancer (4).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
AbstractThe past decade has witnessed a growing role and increasing use of whole-body magnetic resonance imaging (WB-MRI). Driving these successes are developments in both hardware and software that have reduced overall examination times and significantly improved MR imaging quality. In addition, radiologists and clinicians have continued to find promising new applications of this innovative imaging technique that brings together morphologic and functional characterization of tissues. In oncology, the role of WB-MRI has expanded to the point of being recommended in international guidelines for the assessment of several can...
Source: La Radiologia Medica - Category: Radiology Source Type: research
Conclusiones: El tratamiento de la OMAM depende del estadio de la enfermedad; la mandibulectomía es un tratamiento efectivo en el estadio 3 y la secuestrectomía en el estadio 2; el estadio 1 suele controlarse con tratamiento conservador.ABSTRACT Introduction: Bisphosphonates are a family of drugs used to inhibit bone resorption. One of their secondary effects is osteonecrosis of the jaws (ONJ). In 2010, scientists began to publish cases of osteonecrosis of the jaws associated with a new drug, denosumab. In 2014 it was recommended to change the name of ONJ to medication-related osteonecrosis of the jaws (MONJ)...
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
Conclusion - This study suggests the possible involvement of DDC expression in Docetaxel and Mitoxantrone-induced cytotoxicity and apoptosis. PMID: 30417785 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research
Conclusion: PFKFB4 promotes the metastasis of breast cancer cells via induction of HAS2 expression and HA production in a p38-dependent manner. Therefore, the PFKFB4/p38/HAS2 signaling pathway may serve as a potential therapeutic target for metastatic breast cancer.Cell Physiol Biochem 2018;50:2108 –2123
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
The objective of this study was to determine whether Medicare Shared Savings Program (MSSP) ACO enrollment was associated with changes in screening for breast, colorectal, and prostate cancers.MethodsThe authors built a cohort of Medicare beneficiaries from 2006 through 2014 comprising 39,218,652 person ‐years of observation before and 17,252,345 person‐years of observation after MSSP enrollment. The Centers for Medicare&Medicaid Services attribution methodology was recapitulated; and screening services were identified for breast, colorectal, and prostate cancer, implementing both sensitive and specific definitions...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Abstract Acyl-CoA synthetase-4 (ACSL4) is an enzyme implicated in estrogen receptor α (ERα) negative regulation and hormone therapy resistance in breast cancer. In addition, ACSL4 has been associated to certain types of hormone resistance in prostate cancer. Chemotherapeutic treatment of disseminated breast cancer is usually faced with therapy resistance associated to ATP-binding cassette (ABC) transporter expression, which detect and eject anti-cancer drugs from cells. In this context, the aim of the present work was to study the role of ACSL4 in anti-cancer drug resistance and the involvement of ABC ...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research
Publication date: Available online 6 November 2018Source: Journal of Bone OncologyAuthor(s): Stella D'Oronzo, Robert Coleman, Janet Brown, Francesco SilvestrisAbstractBone metastases (BM) are a common complication of cancer, whose management often requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with BM may still experience skeletal-related events and symptomatic skeletal events, with detrimental impact on quality of life and survival.A deeper knowledge of the mechanisms underlying the onset of lytic and sclerotic BM has been acquired in the last decades, leading to the development o...
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | CT Scan | Docetaxel | Genetics | Health | Hormones | Men | PET Scan | Prostate Cancer | Science | Study | Taxotere | Universities